3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
Whole-Body Irradiation
4
Peripheral Blood Stem Cell Transplantation
4
Etoposide
4
Busulfan
4
fludarabine phosphate
3
Mycophenolic Acid
3
Cyclophosphamide
3
Transplantation
2
Tacrolimus
2
Sirolimus
2
Melphalan
2
Cyclosporine
2
fludarabine
1
aldesleukin
1
Whole Genome Sequencing
1
Valganciclovir
1
Tyrosine Kinase Inhibitors
1
Tissue Banks
1
Therapeutics
1
Self Care
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiography, Panoramic
1
Positron-Emission Tomography
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Methotrexate
1
Idarubicin
1
Ganciclovir
1
Foscarnet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Congenital Abnormalities
×
Epirubicin
×
1 year
×
Clear all
No trials found.